14 results about "Retinal ischemia" patented technology

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

The present invention relates to a protein tyrosine kinase inhibitor for the treatment of protein tyrosine kinase-mediated proliferative diseases or symptoms, for example ocular diseases including pathological neovascularization, retinal ischemia, retinal edema, and diabetic retinopathy, as well as malignant tumors. More particularly, the present invention relates to a compound with protein tyrosine kinase inhibitory activity and / or improved solubility and ocular bioavailability, and its uses in the treatment of ocular diseases and malignant tumors.

The invention discloses application of upatinib in preparation of a medicine for treating acute retinal artery occlusion, and belongs to the field of biological medicine. Experimental verification shows that upatinib can remarkably relieve retina ischemia reperfusion injury caused by RAO and improve the survival and functional recovery of ganglion cells; by inhibiting JAK / STAT pathway mediated inflammatory cascade reaction, microglial cell M1 type polarization can be regulated, retinal inflammatory response can be inhibited, proinflammatory factor transcription and inflammatory diffusion can be reduced, and retinal nerve cell injury after RIR can be improved. The invention not only provides a new drug strategy of a targeting molecular mechanism for RAO treatment, but also provides a new theoretical basis for drug redevelopment and precise treatment of ischemic retinopathy, and has a wide application prospect.

The invention relates to the technical field of development of retinal ischemia reperfusion injury medicines, discloses application of Vimentin in preparation of medicines for preventing and treating retinal ischemia reperfusion injury, and discloses a safer and more effective medicine for treating retinal ischemia reperfusion injury. According to the invention, the nerve protection characteristic and good biocompatibility of Vimentin are utilized, so that the side effect of the medicine is reduced, and the treatment safety is improved. In addition, the Vimentin is proved to have a good effect in the aspects of reducing oxidative stress injury and improving mitochondrial functions, and a new therapeutic target is provided for treating the retinal ischemia reperfusion injury. Meanwhile, the Vimentin disclosed by the invention can be used as a supplement or replacement of an existing treatment method, provides a new treatment choice for patients, and is particularly suitable for patients with poor response to traditional treatment medicines.

The invention discloses application of salvianolic acid C in preparation of a medicine for preventing and / or treating retinal ischemia hypoxic nerve injury diseases, and relates to the technical field of biological medicines. The invention proposes and verifies for the first time that salvianolic acid C can significantly promote the formation of stress particles in photoreceptor cells under retinal ischemia and hypoxia conditions, and drives the salvianolic acid C to be assembled into a stress particle-mitochondrial micro-region in a mitochondrial adjacent region. The microcell is enriched in DDX3X, LARP1 and other key RNA binding proteins and multiple mitochondrial related proteins to cooperatively maintain mitochondrial membrane potential, inhibit mPTP opening and reduce ROS generation, so that an endogenous apoptosis pathway is inhibited, and the neuroprotective effect on a photoreceptor is achieved. On the basis, the salvianolic acid C is used for preparing the medicine for preventing and / or treating the retinal ischemia hypoxia nerve injury disease, can be used as a nerve protection supplement for existing anti-VEGF treatment, and has innovativeness and application value.

The invention belongs to the field of biological medicines, and relates to a new pharmaceutical application of miR-126-3p. The invention discloses application of miR-126-3p or a functional equivalent thereof in preparation of a medicine for preventing or treating retinal structure damage and / or retinal function damage caused by retinal ischemia reperfusion injury caused by retinal artery occlusion. According to the medicine, by supplementing endogenous miR-126-3p consumed in the RIRI process, ganglion cell death can be reduced, and the retina structure can be protected; meanwhile, retina electrophysiological signals can be recovered, the retina function is improved, and therefore the core problem that in the prior art, vision of RAO patients is difficult to recover after blood recanalization is solved.

This invention belongs to the field of biotechnology, specifically disclosing a cRGD peptide-functionalized extracellular vesicle derived from mesenchymal stem cells, its preparation method, and its applications. The extracellular vesicle surface is anchored to the cRGD peptide via membrane fusion technology, enabling active targeting and activation of microglia. The preparation method includes isolating and culturing mesenchymal stem cells, purifying natural vesicles by differential ultracentrifugation, and then co-incubating with DSPE-PEG-cRGD for membrane insertion modification. In vitro and in vivo experiments show that the vesicles can be efficiently taken up by activated microglia, delivering endogenous miRNAs, inhibiting the NF-κB pathway, and promoting the transformation of microglia from the M1 to the M2 phenotype. In a retinal ischemia / reperfusion injury model, intravitreal injection of the vesicles reduces retinal ganglion cell apoptosis, protects retinal structure and optic nerve integrity, and restores electroretinogram function. This invention can be used to prepare drugs to alleviate neuroinflammation caused by acute glaucoma.

The invention discloses a targeted retina drug-loaded extracellular vesicle as well as a preparation method and application thereof. The targeted retina drug-loaded extracellular vesicle comprises a lactobacillus-derived extracellular vesicle and a retina ischemia-reperfusion injury related disease treatment drug loaded in the extracellular vesicle, the medicine for treating the diseases related to the retinal ischemia reperfusion injury is indolepropionic acid; the loading capacity of the targeted retina drug-loading extracellular vesicle to indolepropionic acid is (6-8) * 10 <-8 > microgram / particle. The drug-loaded extracellular vesicle has the advantages of high drug loading rate, good biocompatibility, good gastrointestinal tract stability, high bioavailability and good safety. Besides, the extracellular vesicles loaded with indolepropionic acid can carry related marker proteins of retinal neurons through a membrane fusion technology, and can reach an eye retina area more efficiently through peripheral vein administration.

An ophthalmic formulation, its preparation method and use. The ophthalmic formulation comprises a protein tyrosine kinase inhibitor compound. The protein tyrosine kinase inhibitor is used for treating a protein tyrosine kinase-mediated proliferative disease or symptom, such as an eye disease and a malignant tumor accompanied by pathological neovascularization, retinal ischemia, retinal edema, diabetic retinopathy, etc. The formulation can improve the solubility of the compound, achieve a clear solution or a state close to a clear solution, has the potential to prolong the residence time of the compound on the ocular surface, improve the exposure of the ocular fundus tissue, and improve the bioavailability.

The invention discloses a conductive polypyrrole nano-composite based on polydopamine modification, a preparation method of the conductive polypyrrole nano-composite and application of the conductive polypyrrole nano-composite in preparation of a medicine for treating retinal ischemia reperfusion injury, and relates to the technical field of biomedical nano-materials. The polydopamine-modified conductive polypyrrole nano-composite forms a core-shell structure through copolymerization of dopamine and pyrrole monomers, and has the properties of oxidation resistance, iron ion chelation, inflammation resistance and conductivity. The nanocomposite can effectively remove active oxygen, inhibit ferroptosis of retinal ganglion cells, regulate polarization of microglial cells to M2 anti-inflammatory phenotype, and recover the endogenous electrophysiological microenvironment of the retina. In a retina ischemia reperfusion injury model, retina structure injury and function loss are remarkably relieved by injecting P-PPy, and good biocompatibility is shown; and a comprehensive and reliable technical route and evaluation standard are provided for application of the nano-composite in preparation of the medicine for treating the retinal ischemia-reperfusion injury.

The invention provides a DNA tetrahedron drug compound for treating retinal ischemia reperfusion injury, and belongs to the field of eye disease treatment and molecular biology, and the tetrahedron drug compound is connected with YAP saRNA. The tetrahedral drug compound can efficiently and safely deliver YAP saRNA, improve the expression level of YAP in cells and inhibit oxidative stress and ferroptosis of retinal cells, so that RI / RI is effectively treated, and a new choice is provided for treating the tetrahedral drug compound.

The application belongs to the field of application materials, and particularly relates to Ber-ApoEVs and preparation and application thereof, wherein the Ber-ApoEVs comprise ApoEVs and Ber carried by the ApoEVs, wherein the ApoEVs are bone marrow mesenchymal stem cell-derived apoptotic vesicles, and the Ber is berberine and derivatives thereof. Researches of the application show that the brand-new Ber-ApoEVs can play a synergistic neuroprotective effect in regulating microglial cell polarization, inflammatory factor release, p38 / MAPK signal, etc., can reduce neural inflammation caused by retinal ischemia-reperfusion (IR), and inhibit retinal neuron apoptosis, and can be used for treating glaucoma.

The application provides a DNA tetrahedral drug complex for treating retinal ischemia-reperfusion injury, belonging to the field of eye disease treatment and molecular biology, wherein YAP saRNA is connected to the tetrahedral drug complex. The tetrahedral drug complex of the application can efficiently and safely deliver YAP saRNA, increase the expression level of intracellular YAP, inhibit retinal cell oxidative stress and ferroptosis, thereby effectively treating RI / RI, and providing a new choice for the treatment of tetrahedral drug complexes.

The invention provides application of an itaconic acid compound in preparation of a medicine for treating retinal artery occlusion, and belongs to the technical field of treatment of fundus diseases. In particular to new application of itaconic acid and derivatives thereof in preparation of drugs for treating or preventing retinal artery occlusion, the technical cognition of itaconic acid compounds in the traditional application field is broken through, a new small molecule candidate drug is provided for prevention and treatment of retinal ischemic diseases, and the application value is definite. The damage to the structure of the retina in retinal artery occlusion can be relieved, and the visual function is effectively improved; the retina microglial cells can be promoted to be polarized to M2 type, the generation of anti-inflammatory factors IL-10 and TGF beta can be increased, and a protective effect is achieved in the inflammatory response of the retina; the effect of protecting retinal ganglion cells from apoptosis is also achieved. The compound can be used for related diseases such as retinal ischemic diseases, fundus retina inflammation injury and optic nerve injury, and has a wide application prospect for fundus diseases.